Select Cognition Coverage and Published Editorials
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s
Clinical Trials Arena
By Abigail Beaney
July 30, 2025
New Data: Zervimesine for the Treatment of Dementia with Lewy Bodies and Alzheimer Disease
Psychiatric Times
By Leah Kuntz
July 29, 2025
Zervimesine in Alzheimer’s: Cognition Therapeutics and FDA Discuss Phase 2
Clinical Trial Vanguard
By Jon Napitupulu
July 11, 2025
Cognition soars 35% after positive FDA meeting on Alzheimer’s asset zervimesine
Seeking Alpha
By Jonathan Block
July 10, 2025
Cognition Therapeutics Wraps Up FDA Review, Moves Closer to Phase 3 Alzheimer’s Trial
Prism Marketview
By Alex Corbit
July 10, 2025
Armed With Donation From Trial Participant’s Family, Cognition (Nasdaq: CGTX) Initiates Expanded Access Program For Experimental DLB Drug
Benzinga
By Meg Flippin
June 11, 2025
Connect with us on Social Media

